Form 4: Boundless Bio CEO Zachary Hornby Reports Stock Option Grant

Sentiment:

SEC Form 4 Filing


Zachary Hornby, President and CEO of Boundless Bio, Inc., reports the acquisition of stock options.

Summary

  • On March 27, 2024, Zachary Hornby, the President and CEO of Boundless Bio, Inc., reported a transaction related to derivative securities.
  • Hornby acquired stock options for 162,343 shares of common stock.
  • The options have an exercise price of $0.
  • The stock options vest in 48 substantially equal monthly installments beginning on April 27, 2024, and expire on March 26, 2034.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing related to executive compensation and doesn't inherently indicate positive or negative sentiment.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track executive compensation and potential alignment of interests.

Stakeholder Impact

  • The granting of stock options can align management's interests with those of shareholders by incentivizing them to increase the company's value.

Key Dates

DateDescription
03/27/2024Date of stock option transaction
04/27/2024Vesting start date for stock options
03/26/2034Expiration date for stock options

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.